
  
    
      
        Introduction_NNP
        Vancomycin_NNP is_VBZ among_IN the_DT most_RBS effective_JJ antibiotics_NNS for_IN
        treatment_NN of_IN methicillin-resistant_JJ 
        Staphylococcus_NNP aureus_NN infections_NNS [_NN 1_CD ,_,
        2_CD ,_, 3_CD ,_, 4_CD ]_NN ,_, and_CC it_PRP is_VBZ widely_RB used_VBN prophylactically_RB in_IN cardiac_JJ
        surgery_NN [_NN 5_CD ,_, 6_CD ,_, 7_CD ]_NN ._. Among_IN the_DT adverse_JJ effects_NNS of_IN vancomycin_NN
        (_( apart_RB from_IN nephrotoxicity_NN and_CC ototoxicity_NN )_) ,_, anaphylactoid_NN
        reactions_NNS may_MD occur_VB ,_, which_WDT manifest_JJ clinically_RB as_IN cutaneous_JJ
        rash_NN ,_, pruritus_JJ (_( '_POS red_JJ man_NN '_'' syndrome_NN )_) ,_, hypotension_NN and_CC
        broncospasm_NN [_NN 4_CD ,_, 8_CD ,_, 9_CD ]_NN ._. These_DT reactions_NNS are_VBP caused_VBN by_IN
        histamine_NN release_NN ,_, and_CC are_VBP not_RB mediated_JJ by_IN an_DT immunological_JJ
        mechanism_NN [_NN 10_CD ,_, 11_CD ]_NN ._.
        In_IN our_PRP$ cardiosurgical_JJ center_NN vancomycin_NN is_VBZ administered_VBN
        pro-phylactically_JJ before_IN induction_NN of_IN anaesthesia_NN in_IN all_DT
        patients_NNS undergoing_VBG open-heart_JJ surgery_NN ,_, and_CC in_IN some_DT such_JJ
        patients_NNS we_PRP have_VBP observed_VBN the_DT occurrence_NN of_IN pruritus_JJ ,_,
        localized_JJ or_CC generalized_JJ ,_, during_IN infusion_NN of_IN the_DT
        antibiotic_NN ._. We_PRP therefore_RB conducted_VBD the_DT present_JJ study_NN to_TO
        investigate_VB the_DT haemodynamic_JJ behaviour_NN that_WDT follows_VBZ the_DT
        occurrence_NN of_IN pruritus_JJ ,_, and_CC to_TO compare_VB it_PRP with_IN that_DT
        observed_VBD in_IN patients_NNS who_WP are_VBP free_JJ from_IN this_DT clinical_JJ
        sign_NN ._.
      
      
        Patients_NNS and_CC methods_NNS
        We_PRP studied_VBD 50_CD patients_NNS undergoing_VBG elective_JJ coronary_JJ
        artery_NN bypass_NN surgery_NN ,_, following_VBG approval_NN from_IN the_DT local_JJ
        ethics_NNS committee_NN and_CC once_RB written_VBN informed_VBN consent_NN had_VBD been_VBN
        obtained_VBN from_IN each_DT patient_NN ._. Admission_NNP criteria_NNS to_TO the_DT study_NN
        were_VBD as_IN follows_VBZ :_: stable_JJ preoperative_JJ haemodynamic_JJ
        conditions_NNS ,_, no_DT intravenous_JJ cardiovascular_JJ therapy_NN ,_, no_DT
        preoperative_JJ diuretic_JJ therapy_NN ,_, sinus_JJ rhythm_NN ,_, no_DT history_NN of_IN
        anaphylactic_JJ reactions_NNS ,_, and_CC normal_JJ hepatic_JJ and_CC renal_JJ
        function_NN ._.
        Preoperative_NNP therapy_NN was_VBD continued_VBN until_IN the_DT morning_NN of_IN
        the_DT operation_NN ._. Premedication_NNP consisted_VBD of_IN morphine_NN (_( 0_CD ._. 1_LS
        mg_NN /_NN kg_NN )_) and_CC scopolamine_NN (_( 0_CD ._. 005_CD mg_NN /_NN kg_NN )_) ,_, administered_VBN
        intramuscularly_RB 1_CD hour_NN before_IN the_DT patient_NN entered_VBD the_DT
        operating_VBG room_NN ._. After_IN the_DT monitoring_VBG devices_NNS had_VBD been_VBN
        positioned_VBN (_( electrocardiograph_NN leads_VBZ DII-V_NNP 5_CD for_IN ST-segment_NNP
        analysis_NN ;_: radial_NN artery_NN cannula_NN and_CC pulmonary_JJ artery_NN
        catheter_NN [_NN Arrow_NNP AH_NNP 050050_CD -_: H_NNP ,_, 7_CD ._. 5_CD F_NN ;_: Arrow_NNP International_NNP ,_,
        Inc_NNP ._. ,_, Reading_VBG ,_, PA_NNP ,_, USA_NNP ]_NN transcuta-neous_JJ oxygen_NN saturation_NN
        probe_NN )_) ,_, vancomycin_NN (_( 15_CD mg_NN /_NN kg_NN )_) was_VBD administered_VBN at_IN a_DT
        constant_JJ rate_NN by_IN a_DT syringe_NN pump_NN (_( DPS_NNP Fre-senius_NNP ;_: Grenoble_NNP ,_,
        France_NNP )_) over_IN 30_CD min_NN ._.
        A_DT complete_JJ haemodynamic_JJ profile_NN was_VBD taken_VBN for_IN each_DT
        patient_NN at_IN the_DT following_VBG time_NN points_NNS :_: before_IN the_DT
        administration_NN of_IN vancomycin_NN (_( time_NN point_NN 1_LS )_) ;_: at_IN 15_CD (_( time_NN
        point_NN 2_LS )_) and_CC 30_CD min_NN (_( time_NN point_NN 3_LS )_) after_IN the_DT beginning_NN of_IN
        vancomycin_NN infusion_NN ;_: and_CC 15_CD min_NN after_IN vancomycin_NN infusion_NN
        had_VBD been_VBN stopped_VBN (_( time_NN point_NN 4_LS )_) ._. Apart_RB from_IN collection_NN of_IN
        haemodynamic_JJ data_NNS ,_, at_IN each_DT time_NN point_NN two_CD blood_NN samples_NNS
        were_VBD drawn_VBN (_( one_CD from_IN the_DT radial_NN artery_NN cannula_NN and_CC another_DT
        from_IN the_DT distal_NN port_NN of_IN the_DT pulmonary_JJ artery_NN catheter_NN )_) in_IN
        order_NN to_TO measure_VB arterial_NN and_CC mixed_JJ venous_JJ blood_NN parameters_NNS
        that_WDT are_VBP necessary_JJ for_IN calculation_NN of_IN Qsp_NNP /_NN Qt_NNP (_( i_NNP ._. e_SYM ._.
        haemoglobin_NN concentration_NN ,_, and_CC oxygen_NN tension_NN and_CC
        saturation_NN )_) ._.
        Each_DT haemodynamic_JJ profile_NN consisted_VBD of_IN parameters_NNS
        measured_VBN directly_RB (_( i_NNP ._. e_SYM ._. heart_NN rate_NN ,_, systemic_JJ and_CC pulmonary_JJ
        pressures_NNS ,_, pulmonary_JJ capillary_JJ wedge_NN pressure_NN ,_, central_JJ
        venous_JJ pressure_NN and_CC cardiac_JJ output_NN )_) and_CC those_DT that_WDT were_VBD
        calculated_VBN (_( i_NNP ._. e_SYM ._. SVRI_NNP ,_, pulmonary_JJ vascular_NN resistance_NN index_NN
        [_NN PVRI_NNP ]_NN ,_, CI_NNP and_CC SVI_NNP )_) ._.
        The_DT pulmonary_JJ shunt_NN fraction_NN (_( Qsp_NNP /_NN Qt_NNP )_) was_VBD calculated_VBN
        using_VBG the_DT following_NN equation_NN [_NN 12_CD ]_NN :_:
        
        Where_WRB CcO_NNP 
        2_CD is_VBZ the_DT pulmonary_JJ capillary_JJ oxygen_NN
        content_NN ,_, CaO_NNP 
        2_CD is_VBZ the_DT arterial_NN oxygen_NN content_NN ,_, and_CC
        CvO_NNP 
        2_CD is_VBZ the_DT mixed_JJ venous_JJ oxygen_NN
        content_NN ._.
        Analysis_NNP of_IN the_DT blood_NN samples_NNS was_VBD performed_VBN by_IN the_DT same_JJ
        operator_NN ,_, using_VBG a_DT blood_NN gas_NN system_NN (_( model_NN 288_CD ;_: Ciba_NNP
        Corning_NNP ,_, Medfield_NNP ,_, MA_NNP ,_, USA_NNP )_) located_VBN just_RB outside_IN the_DT
        operating_VBG room_NN ._.
        During_IN the_DT study_NN all_DT patients_NNS breathed_VBD room_NN air_NN ,_, and_CC
        crystalloid_NN was_VBD continuously_RB infused_VBN at_IN a_DT rate_NN of_IN 2_CD ml_NN /_NN kg_NN
        per_IN hour_NN ,_, which_WDT was_VBD increased_VBN if_IN necessary_JJ to_TO offset_VB a_DT
        moderate_JJ reduction_NN in_IN systemic_JJ arterial_NN pressure_NN ._. If_IN mean_NN
        blood_NN pressure_NN decreased_VBN by_IN more_JJR than_IN 20_CD %_NN ,_, then_RB more_JJR fluids_NNS
        and_CC /_NN or_CC boluses_NNS of_IN ephedrine_NN were_VBD infused_VBN ,_, vancomycin_NN
        infusion_NN was_VBD temporarily_RB discontinued_VBN and_CC the_DT patient_NN was_VBD
        excluded_VBN from_IN the_DT study_NN ._.
        The_DT patients_NNS were_VBD divided_VBN into_IN two_CD groups_NNS :_: group_NN A_DT ,_,
        including_VBG patients_NNS who_WP exhibited_VBN pruritus_JJ during_IN vancomycin_NN
        infusion_NN ;_: and_CC group_NN B_NNP ,_, including_VBG those_DT patients_NNS who_WP did_VBD not_RB
        exhibit_VB pruritis_NNS ._. Each_DT group_NN was_VBD then_RB divided_VBN into_IN two_CD
        subgroups_NNS on_IN the_DT basis_NN of_IN preoperative_JJ therapy_NN with_IN a_DT
        β-blocker_JJ ;_: subgroups_NNS A_DT 1_CD and_CC B_NNP 1_CD were_VBD treated_VBN with_IN a_DT
        β-blocker_JJ ,_, whereas_IN subgroups_NNS A_DT 2_CD and_CC B_NNP 2_CD were_VBD not_RB ._.
        The_DT results_NNS are_VBP expressed_VBN as_IN mean_NN ±_NN standard_JJ deviation_NN ._.
        Data_NNP were_VBD analysed_JJ using_VBG Student_NNP 's_POS t-test_JJ and_CC analysis_NN of_IN
        variance_NN with_IN Bonferroni_NNP correction_NN ._. 
        P_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN
        statistically_RB significant_JJ ._.
      
      
        Results_NNS
        Group_NNP A_DT included_VBD 17_CD patients_NNS (_( subgroup_NN A_DT 1_CD ,_, 
        n_NN =_SYM 11_CD ;_: and_CC subgroup_NN A_DT 2_CD ,_, 
        n_NN =_SYM 6_CD )_) and_CC group_NN B_NNP included_VBD 28_CD
        patients_NNS (_( subgroup_NN B_NNP 1_CD ,_, 
        n_NN =_SYM 17_CD ;_: and_CC subgroup_NN B_NNP 2_CD ,_, 
        n_NN =_SYM 11_CD )_) ._. Five_CD patients_NNS were_VBD excluded_VBN
        from_IN the_DT study_NN because_IN of_IN reduction_NN in_IN mean_NN blood_NN pressure_NN
        by_IN more_JJR than_IN 20_CD %_NN (_( 
        n_NN =_SYM 2_LS )_) ,_, angina_NN (_( 
        n_NN =_SYM 1_CD ,_, treated_VBN with_IN the_DT intravenous_JJ
        administration_NN of_IN nitroglycerin_NN )_) and_CC intolerable_JJ pruritus_JJ (_(
        
        n_NN =_SYM 2_LS )_) ._.
        Data_NNS on_IN the_DT general_JJ characteristics_NNS of_IN the_DT patients_NNS are_VBP
        provided_VBN in_IN Table_NNP 1_CD ._. There_EX were_VBD no_DT significant_JJ differences_NNS
        between_IN the_DT groups_NNS in_IN terms_NNS of_IN age_NN ,_, weight_NN ,_, preoperative_JJ
        left_JJ ventricular_NN ejection_NN fraction_NN ,_, preoperative_JJ therapy_NN ,_,
        or_CC basal_NN haemodynamic_JJ and_CC respiratory_JJ data_NNS (_( time_NN point_NN 1_CD ,_,
        Table_NNP 1_LS )_) ._. Table_NNP 2_CD lists_NNS the_DT mean_NN amounts_NNS of_IN fluids_NNS infused_VBN
        during_IN the_DT study_NN ._.
        At_IN time_NN point_NN 3_CD as_IN compared_VBN with_IN time_NN point_NN 1_CD ,_, patients_NNS
        in_IN group_NN A_DT exhibited_VBN a_DT significant_JJ reduction_NN (_( 
        P_NN <_NN 0_CD ._. 05_CD )_) in_IN SVRI_NNP and_CC PVRI_NNP ,_, and_CC a_DT
        significant_JJ increase_NN (_( 
        P_NN <_NN 0_CD ._. 05_CD )_) in_IN CI_NNP and_CC SVI_NNP (_( Table_NNP 3_LS )_) ._.
        Heart_NNP rate_NN and_CC mean_VB systemic_JJ arterial_NN pressure_NN exhibited_VBN a_DT
        slight_JJ but_CC not_RB significant_JJ decrease_NN ,_, whereas_IN the_DT other_JJ
        haemodynamic_JJ parameters_NNS remained_VBD stable_JJ ._. At_IN time_NN points_NNS 2_CD
        and_CC 4_CD there_EX were_VBD no_DT significant_JJ changes_NNS in_IN haemodynamic_JJ
        parameters_NNS as_IN compared_VBN with_IN time_NN point_NN 1_CD ._.
        Patients_NNS in_IN group_NN B_NNP and_CC in_IN subgroups_NNS A_DT 1_CD ,_, B_NNP 1_CD ,_, and_CC B_NNP 2_CD did_VBD
        not_RB show_VB any_DT significant_JJ haemodynamic_JJ change_NN throughout_IN the_DT
        study_NN (_( Tables_NNP 4_CD and_CC 5_LS )_) ._. However_RB ,_, patients_NNS of_IN subgroup_NN A_DT 2_CD
        showed_VBD a_DT significant_JJ increase_NN (_( 
        P_NN <_NN 0_CD ._. 05_CD )_) in_IN heart_NN rate_NN (_( versus_CC
        time_NN point_NN 2_LS )_) ,_, CI_NNP and_CC SVI_NNP ,_, and_CC a_DT significant_JJ decrease_NN (_( 
        P_NN <_NN 0_CD ._. 05_CD )_) in_IN SVRI_NNP and_CC PVRI_NNP at_IN time_NN
        point_NN 3_CD as_IN compared_VBN with_IN time_NN point_NN 1_CD (_( Table_NNP 4_LS )_) ._.
        PaO_NNP 
        2_CD and_CC arterial_NN carbon_NN dioxide_NN tension_NN ,_,
        arterial_NN oxygen_NN saturation_NN and_CC Qsp_NNP /_NN Qt_NNP did_VBD not_RB change_VB
        significantly_RB in_IN patients_NNS of_IN subgroups_NNS A_DT 1_CD ,_, B_NNP 1_CD ,_, B_NNP 2_CD ,_, and_CC
        group_NN B_NNP throughout_IN the_DT study_NN (_( Tables_NNP 3_CD ,_, 4_CD ,_, 5_LS )_) ._. However_RB ,_, PaO_NNP
        
        2_LS and_CC arterial_NN oxygen_NN saturation_NN showed_VBD
        a_DT significant_JJ reduction_NN ,_, and_CC Qsp_NNP /_NN Qt_NNP a_DT significant_JJ increase_NN
        at_IN time_NN point_NN 3_CD as_IN compared_VBN with_IN time_NN point_NN 1_CD in_IN patients_NNS
        of_IN group_NN A_DT and_CC subgroup_NN A_DT 2_CD (_( Tables_NNP 3_CD and_CC 4_LS )_) ._.
        In_IN the_DT majority_NN of_IN cases_NNS studied_VBD pruritus_JJ was_VBD mild_JJ or_CC
        moderate_JJ ,_, and_CC localized_JJ on_IN the_DT scalp_NN ,_, face_NN ,_, neck_NN or_CC upper_JJ
        torso_NN ._. In_IN a_DT few_JJ cases_NNS it_PRP was_VBD severe_JJ and_CC spread_VB all_DT over_IN the_DT
        body_NN surface_NN ._. In_IN four_CD cases_NNS pruritis_NNS was_VBD accompanied_VBN by_IN a_DT
        cutaneous_JJ rash_NN ,_, and_CC no_DT other_JJ clinical_JJ sign_NN was_VBD
        observed_VBN ._.
      
      
        Discussion_NNP
        The_DT development_NN of_IN pruritus_JJ ,_, an_DT important_JJ symptom_NN of_IN
        histamine_NN release_NN ,_, is_VBZ relatively_RB frequent_JJ with_IN vancomycin_NN
        administration_NN [_NN 2_CD ,_, 3_CD ,_, 4_CD ]_NN ._. It_PRP generally_RB appears_VBZ alone_RB ,_, but_CC
        sometimes_RB it_PRP is_VBZ associated_VBN with_IN headache_NN ;_: flushing_VBG ;_:
        erythematous_JJ rash_NN over_IN the_DT face_NN ,_, neck_NN and_CC upper_JJ torso_NN (_( the_DT
        so-called_NN '_POS red_JJ man_NN '_'' syndrome_NN )_) ;_: hypotension_NN ;_: and_CC broncospasm_NN
        [_NN 4_CD ,_, 13_CD ,_, 14_CD ,_, 15_CD ]_NN ._. One_CD of_IN the_DT most_RBS important_JJ factors_NNS that_WDT
        impact_NN on_IN the_DT incidence_NN of_IN these_DT adverse_JJ reactions_NNS is_VBZ the_DT
        vancomycin_NN infusion_NN rate_NN ._. For_IN example_NN ,_, Renz_NNP and_CC coworkers_NNS [_NN
        11_CD ]_NN infused_VBN 1_CD g_SYM vancomycin_NN over_IN 10_CD min_NN to_TO patients_NNS
        scheduled_VBN for_IN elective_JJ prosthetic_JJ joint_JJ replacement_NN ,_, and_CC
        found_VBD that_IN 90_CD %_NN of_IN patients_NNS had_VBD rash_NN and_CC pruritus_JJ ,_, and_CC 50_CD %_NN
        had_VBD significant_JJ hypotension_NN ._. Also_RB ,_, Valero_NNP and_CC coworkers_NNS [_NN
        7_CD ]_NN administered_VBN 1_CD g_SYM vancomycin_NN over_IN 30_CD min_NN to_TO cardiac_JJ
        surgical_JJ patients_NNS and_CC observed_VBD hypotension_NN in_IN 25_CD %_NN of_IN cases_NNS ._.
        For_IN this_DT reason_NN ,_, the_DT international_JJ literature_NN recommends_VBZ
        that_DT vancomycin_NN be_VB infused_VBN over_IN a_DT period_NN of_IN 60_CD min_NN in_IN order_NN
        to_TO prevent_VB these_DT side_NN effects_NNS ,_, and_CC hypotension_NN in_IN
        particular_NN ,_, which_WDT in_IN some_DT cases_NNS manifests_NNS as_IN
        life-threatening_JJ shock_NN [_NN 6_CD ,_, 8_CD ,_, 9_CD ,_, 16_CD ]_NN ._.
        The_DT present_JJ study_NN was_VBD conducted_VBN to_TO investigate_VB the_DT
        haemodynamic_JJ changes_NNS that_WDT occur_VBP following_VBG the_DT appearance_NN of_IN
        pruritus_JJ ._. We_PRP therefore_RB opted_VBD to_TO administer_VB vancomycin_NN over_IN
        a_DT period_NN of_IN 30_CD min_NN in_IN order_NN to_TO encourage_VB appearance_NN of_IN the_DT
        sign_NN ,_, as_IN the_DT coronary_JJ patients_NNS were_VBD adequately_RB monitored_VBN
        and_CC the_DT anaesthetist_NN was_VBD therefore_RB in_IN the_DT optimal_NN
        conditions_NNS to_TO detect_VB and_CC treat_VB any_DT change_NN in_IN
        cardiorespiratory_NN function_NN at_IN an_DT early_JJ stage_NN ._.
        Our_PRP$ analysis_NN of_IN haemodynamic_JJ profiles_NNS shows_VBZ that_IN ,_, in_IN
        those_DT patients_NNS who_WP exhibited_VBN pruritus_JJ (_( group_NN A_DT )_) ,_, systemic_JJ
        vascular_NN resistance_NN fell_VBD significantly_RB 30_CD min_NN after_IN
        initiation_NN of_IN vancomycin_NN administration_NN ._. This_DT effect_NN was_VBD
        transient_JJ ,_, disappearing_VBG 15_CD min_NN later_RB ._. The_DT reduction_NN in_IN
        systemic_JJ vascular_NN resistance_NN was_VBD not_RB accompanied_VBN by_IN a_DT
        significant_JJ decrease_NN in_IN systemic_JJ arterial_NN pressure_NN ,_, and_CC
        because_IN heart_NN rate_NN was_VBD unchanged_JJ ,_, the_DT increase_NN in_IN stroke_NN
        volume_NN offset_VBD the_DT peripheral_JJ vasodilatation_NN induced_VBN by_IN the_DT
        antibiotic_NN ._. On_IN the_DT contrary_NN ,_, in_IN patients_NNS free_JJ from_IN pruritus_JJ
        (_( group_NN B_NNP )_) ,_, those_DT haemodynamic_JJ changes_NNS were_VBD not_RB observed_VBN and_CC
        all_DT of_IN the_DT parameters_NNS considered_VBN remained_VBD stable_JJ throughout_IN
        the_DT study_NN ._. In_IN group_NN A_DT the_DT normovolaemic_JJ condition_NN of_IN the_DT
        patients_NNS and_CC the_DT fluids_NNS infused_VBN during_IN the_DT study_NN
        undoubtedly_RB contributed_VBD to_TO haemodynamic_JJ compensation_NN ._.
        However_RB ,_, it_PRP may_MD be_VB supposed_VBN that_IN if_IN vancomycin_NN is_VBZ
        administered_VBN to_TO an_DT hypovolaemic_JJ patient_NN then_RB this_DT
        compensation_NN cannot_NN be_VB as_IN effective_NN and_CC hypotension_NN may_MD
        occur_VB ._. We_PRP were_VBD unable_JJ to_TO confirm_VB this_DT for_IN two_CD reasons_NNS :_:
        first_JJ ,_, hypovolaemia_NN was_VBD among_IN the_DT exclusion_NN criteria_NNS ;_: and_CC
        second_JJ ,_, we_PRP considered_VBD exposure_NN of_IN a_DT coronary_JJ patient_NN to_TO the_DT
        additional_JJ stress_NN of_IN relative_JJ hypovolaemia_NN to_TO be_VB harmful_JJ ._.
        However_RB ,_, considering_VBG the_DT different_JJ amounts_NNS of_IN crystalloid_NN
        infused_VBN in_IN each_DT group_NN ,_, we_PRP can_MD indirectly_RB deduce_NN that_IN fluid_JJ
        compensation_NN contributed_VBD to_TO the_DT maintenance_NN of_IN stable_JJ
        values_NNS for_IN mean_NN systemic_JJ pressure_NN when_WRB systemic_JJ vascular_NN
        resistance_NN decreased_VBD ._.
        The_DT stability_NN of_IN heart_NN rate_NN in_IN face_NN of_IN a_DT reduction_NN in_IN
        systemic_JJ vascular_NN resistance_NN in_IN group_NN A_DT patients_NNS renders_NNS
        possible_JJ an_DT influence_NN of_IN preoperative_JJ β-blocker_JJ therapy_NN on_IN
        haemodynamic_JJ compensation_NN ._. Confirmation_NNP of_IN this_DT is_VBZ
        indicated_VBN by_IN the_DT different_JJ trends_NNS of_IN heart_NN rate_NN in_IN the_DT
        group_NN A_DT patients_NNS who_WP were_VBD treated_VBN with_IN a_DT β-blocker_JJ as_IN
        compared_VBN with_IN those_DT who_WP were_VBD not_RB ._. The_DT stability_NN of_IN heart_NN
        rate_NN in_IN subgroup_NN A_DT 1_CD and_CC the_DT significant_JJ increase_NN in_IN
        subgroup_NN A_DT 2_CD represents_VBZ proof_NN that_IN β-blocker_JJ therapy_NN limited_JJ
        that_IN compensatory_JJ mechanism_NN to_TO peripheral_JJ vasodilatation_NN ._.
        Surprisingly_RB ,_, assessment_NN of_IN other_JJ haemodynamic_JJ parameters_NNS
        (_( SVRI_NNP ,_, CI_NNP ,_, SVI_NNP )_) revealed_VBD a_DT significant_JJ change_NN only_RB in_IN those_DT
        patients_NNS who_WP were_VBD affected_VBN by_IN pruritus_JJ and_CC not_RB treated_VBN with_IN
        a_DT β-blocker_JJ ,_, as_IN though_IN treatment_NN had_VBD antagonized_JJ all_DT of_IN the_DT
        cardiovascular_JJ effects_NNS triggered_VBN by_IN the_DT release_NN of_IN
        histamine_NN during_IN vancomycin_NN administration_NN ._. However_RB ,_,
        because_IN the_DT number_NN of_IN the_DT patients_NNS studied_VBN was_VBD small_JJ ,_, these_DT
        findings_NNS require_VBP further_JJ investigation_NN and_CC confirmation_NN in_IN
        larger_JJR studies_NNS ._.
        The_DT significant_JJ increase_NN in_IN Qsp_NNP /_NN Qt_NNP and_CC decrease_VB in_IN PaO_NNP 
        2_CD in_IN the_DT patients_NNS affected_VBN by_IN pruritus_JJ
        can_MD be_VB interpreted_VBN as_IN the_DT effect_NN of_IN an_DT imbalance_NN in_IN the_DT
        ventilation_NN /_NN perfusion_NN ratio_NN ,_, induced_VBN by_IN the_DT vasodilating_VBG
        action_NN of_IN vancomycin_NN on_IN the_DT pulmonary_JJ circulation_NN ,_, as_IN
        supported_VBN by_IN the_DT significant_JJ reduction_NN in_IN pulmonary_JJ
        vascular_NN resistance_NN at_IN time_NN point_NN 3_CD ._. Also_RB ,_, the_DT respiratory_JJ
        changes_NNS were_VBD significant_JJ only_RB in_IN patients_NNS of_IN group_NN A_DT who_WP
        were_VBD not_RB treated_VBN with_IN a_DT β-blocker_JJ ,_, whereas_IN preopera-tive_JJ
        use_NN of_IN the_DT drug_NN eliminated_VBD any_DT significant_JJ respiratory_JJ
        change_NN ._. The_DT degree_NN of_IN reduction_NN in_IN PaO_NNP 
        2_CD was_VBD moderate_JJ and_CC had_VBD no_DT important_JJ
        impact_NN on_IN arterial_NN haemostasis_NNS in_IN the_DT patients_NNS studied_VBN ,_, who_WP
        showed_VBD however_RB normal_JJ preoperative_JJ respiratory_JJ
        function_NN ._.
        A_DT limitation_NN in_IN the_DT calculation_NN of_IN Qsp_NNP /_NN Qt_NNP was_VBD that_IN the_DT
        patients_NNS were_VBD breathing_VBG room_NN air_NN during_IN the_DT study_NN ._. In_IN such_JJ
        conditions_NNS ,_, apart_RB from_IN changes_NNS in_IN the_DT Qsp_NNP /_NN Qt_NNP ,_, the_DT decrease_NN
        in_IN PaO_NNP 
        2_CD may_MD be_VB caused_VBN by_IN effects_NNS of_IN
        maldistribution_NN in_IN the_DT ventilation_NN /_NN perfusion_NN ratio_NN ._. For_IN
        this_DT reason_NN we_PRP must_MD consider_VB the_DT Qsp_NNP /_NN Qt_NNP not_RB as_IN an_DT absolute_JJ
        value_NN but_CC as_IN a_DT relative_JJ one_CD ,_, but_CC we_PRP can_MD nevertheless_RB
        attribute_VB meaning_VBG to_TO changes_NNS in_IN this_DT parameter_NN [_NN 12_CD ]_NN ._.
        On_IN the_DT basis_NN of_IN the_DT results_NNS obtained_VBN ,_, we_PRP conclude_VBP that_DT
        occurrence_NN of_IN pruritus_JJ during_IN vancomycin_NN administration_NN
        must_MD be_VB considered_VBN an_DT alarm_NN bell_NN that_WDT indicates_VBZ the_DT
        presence_NN of_IN peripheral_JJ vasodilatation_NN ._. It_PRP can_MD help_VB the_DT
        physician_NN to_TO identify_VB at_IN an_DT early_JJ stage_NN those_DT patients_NNS who_WP
        are_VBP at_IN risk_NN for_IN hypotension_NN (_( e_SYM ._. g_SYM ._. hypovolaemic_JJ patient_NN )_) and_CC
        to_TO compensate_VB for_IN hypovolaemia_NN before_IN continuing_VBG
        administration_NN of_IN vancomycin_NN ._. This_DT benefit_NN is_VBZ useful_JJ not_RB so_RB
        much_RB in_IN intensive_JJ care_NN units_NNS (_( where_WRB patients_NNS are_VBP
        continuously_RB and_CC adequately_RB monitored_VBN )_) as_IN in_IN medical_JJ and_CC
        surgical_JJ departments_NNS overall_JJ ,_, where_WRB monitoring_NN of_IN arterial_NN
        pressure_NN is_VBZ not_RB continuous_JJ and_CC nurse_NN care_NN is_VBZ not_RB as_RB strict_JJ
        as_IN in_IN the_DT intensive_JJ care_NN unit_NN ._.
        Finally_RB ,_, the_DT lack_NN of_IN haemodynamic_JJ and_CC respiratory_JJ
        changes_NNS in_IN the_DT patients_NNS affected_VBN by_IN pruritus_JJ and_CC treated_VBN
        with_IN a_DT β-blocker_JJ before_IN surgery_NN makes_VBZ it_PRP probable_JJ that_IN
        these_DT agents_NNS can_MD confer_VB protection_NN against_IN the_DT
        anaphylactoid_NN reactions_NNS that_WDT are_VBP mediated_JJ by_IN release_NN of_IN
        histamine_NN ._.
      
      
        Key_JJ messages_NNS
        ·_NN Pruritus_NNP ,_, which_WDT may_MD occur_VB during_IN vancomycin_NN
        administration_NN ,_, can_MD be_VB considered_VBN an_DT alarm_NN bell_NN ,_, indicating_VBG
        the_DT presence_NN of_IN peripheral_JJ vasodilatation_NN ._.
        ·_NN The_DT physician_NN encountering_VBG pruritus_JJ during_IN vancomycin_NN
        administration_NN must_MD correct_VB the_DT condition_NN of_IN hypovolaemia_NN
        before_IN continuing_VBG vancomycin_NN infusion_NN ._.
        ·_NN Pruritus_NNP is_VBZ also_RB associated_VBN with_IN a_DT slight_JJ but_CC
        significant_JJ reduction_NN in_IN PaO_NNP 
        2_CD and_CC increase_NN in_IN Qsp_NNP /_NN Qt_NNP ._.
        ·_NN Patients_NNPS affected_VBN by_IN pruritus_JJ during_IN vancomycin_NN
        infusion_NN but_CC who_WP were_VBD treated_VBN with_IN a_DT β-blocker_JJ before_IN
        surgery_NN did_VBD not_RB exhibit_VB any_DT significant_JJ haemodynamic_JJ or_CC
        respiratory_JJ change_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        CI_NNP =_SYM cardiac_JJ index_NN ;_: PaO_NNP 
        2_CD =_SYM arterial_NN oxygen_NN tension_NN ;_: PVRI_NNP =_SYM
        pulmonary_JJ vascular_NN resistance_NN index_NN ;_: Qsp_NNP /_NN Qt_NNP =_SYM shunt_NN
        fraction_NN ;_: SVI_NNP =_SYM stroke_NN volume_NN index_NN ;_: SVRI_NNP =_SYM systemic_JJ
        vascular_NN resistance_NN index_NN ._.
      
    
  
